Tamoxifen is an antagonist of the estrogen receptor in breast tissue, and is marketed under the tradenames Nolvadex®, Istubal® and Valodex®?. . It is prescribed as an adjuvant treatment for estrogen receptor (ER) positive breast cancer in pre-menopausal women. Tamoxifen has been used for more than 30 years, and is also prescribed for other indications. It is known that some individuals do not respond to tamoxifen due to genetic variations. These individuals do not derive the intended benefit of tamoxifen, and are unnecessarily exposed to potential side effects.This test determines whether the patient has a genetic variant that causes them to be a poor metabolizer or non-matabolizer of tamoxifen. Tamoxifen is less effective or not effective in these individuals, and it is recommended that their physician choose other types of adjuvant treatment.
We have not reviewed this DNA test yet. If you have taken this test, please scroll down and click “Add your review.” All DNA tests that have not been reviewed receive a default score of 6/10 until reader reviews change the score.
Tamoxifen is an antagonist of the estrogen receptor in breast tissue, and is marketed under the tradenames Nolvadex?, Istubal? and Valodex?. . It is prescribed as an adjuvant treatment for estrogen receptor (ER) positive breast cancer in pre-menopausal women. Tamoxifen has been used for more than 30 years, and is also prescribed for other indications. It is known that some individuals do not respond to tamoxifen due to genetic variations. These individuals do not derive the intended benefit of tamoxifen, and are unnecessarily exposed to potential side effects.This test determines whether the patient has a genetic variant that causes them to be a poor metabolizer or non-matabolizer of tamoxifen. Tamoxifen is less effective or not effective in these individuals, and it is recommended that their physician choose other types of adjuvant treatment.
Tamoxifen is an antagonist of the estrogen receptor in breast tissue, and is marketed under the tradenames Nolvadex®, Istubal® and Valodex®?. . It is prescribed as an adjuvant treatment for estrogen receptor (ER) positive breast cancer in pre-menopausal women. Tamoxifen has been used for more than 30 years, and is also prescribed for other indications. It is known that some individuals do not respond to tamoxifen due to genetic variations. These individuals do not derive the intended benefit of tamoxifen, and are unnecessarily exposed to potential side effects.This test determines whether the patient has a genetic variant that causes them to be a poor metabolizer or non-matabolizer of tamoxifen. Tamoxifen is less effective or not effective in these individuals, and it is recommended that their physician choose other types of adjuvant treatment.
